Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SEN0014196

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Abstract The human sirtuin silent information regulator 1 (SIRT1) is a NAD+-dependent deacetylase enzyme. It deacetylates many… Expand
2015
2015
AIM Selisistat (SEN0014196), a first-in-class SirT1 inhibitor, is being developed as a disease-modifying therapy for Huntington's… Expand
2012
2012
Background Siena Biotech SpA is developing selisistat (SEN0014196) as a potentially disease-modifying therapy for HD. Selsistat… Expand
2012
2012
To date no disease modifying therapy has shown efficacy in Huntington's Disease (HD). The PADDINGTON (Pharmacodynamic Approaches… Expand
2012
2012
Background Siena Biotech SpA is developing selisistat (SEN0014196) as a potentially disease-modifying therapy for HD. Selisistat… Expand
2012
2012
Background Siena Biotech SpA is developing selisistat (SEN0014196) as a potentially disease-modifying therapy for HD. Selsistat… Expand